MPA given orally during the first trimester for threatened miscarriage carries no specific risk for foetal abnormalities albeit the rate is higher than non-threatened pregnancies

• Autorzy: Yovich J.L. , Mariappen U. , Hinchliffe P.M. , Dhalival S.S. , Keane K.N.
• Języki publikacji: EN

Abstrakty

EN

• Wydawca: -
• Czasopismo: Reproductive Biology
• Rocznik: 2020
• Tom: 20
• Numer: 3
• Opis fizyczny: p.424-432,fig.,ref.

Twórcy

autor

Yovich J.L.

• PIVET Medical Centre, Perth 6007, WA, Australia
• School of Pharmacy and Biomedical Science, Faculty of Health Sciences, Curtin University, Perth 6845, WA, Australia

autor

Mariappen U.

• School of Pharmacy and Biomedical Science, Faculty of Health Sciences, Curtin University, Perth 6845, WA, Australia
• Hospital Tengku Ampuan Rahimah (HTAR), Klang, Malaysia

autor

Hinchliffe P.M.

• School of Pharmacy and Biomedical Science, Faculty of Health Sciences, Curtin University, Perth 6845, WA, Australia

autor

Dhalival S.S.

• School of Public Health, Faculty of Health Sciences, Curtin University, Perth 6845, WA, Australia

autor

Keane K.N.

• PIVET Medical Centre, Perth 6007, WA, Australia
• School of Pharmacy and Biomedical Science, Faculty of Health Sciences, Curtin University, Perth 6845, WA, Australia

Identyfikatory

DOI

10.1016/j.repbio.2020.03.008